Posts tagged GILD


Gilead Sciences, Inc. (GILD) Has More Drivers At Play Than Just Crumbling HCV Segment: J.P. Morgan

Cory Kasimov is enthusiastic on GILD’s CAR-T therapy Yescarta as well as M&A strategy.

Read more

Gilead Sciences, Inc.’s (GILD) Q3:17 Earnings Send Shares Lower

Gilead Sciences, Inc. (NASDAQ:GILD) shares fell nearly 4% in the extended session Thursday after the …

Read more

Gilead Sciences, Inc. (GILD) Takes Promising Step with NASH Asset, Cheers J.P. Morgan

Cory Kasimov: GILD’s Phase II study data may be early, but first signs speak to a well-tolerated treatment.

Read more

Analysts Chime in on Celgene Corporation (CELG) Crohn’s Dud and Gilead Sciences, Inc. (GILD) Winning FDA Nod for Yescarta

Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.

Read more

‘Stock Market Wizard’ Michael Masters Puts His Money on Transenterix Inc (TRXC), Says Bye Bye to Gilead Sciences, Inc. (GILD)

Did this $4 billion fund make the right call on these two soaring biotechs?

Read more

Gilead Sciences, Inc. (GILD) Presents Phase 3 Clinical Data in HIV-1 at IDWeek 2017

Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating …

Read more

Gilead Sciences, Inc. (GILD) Obtains CFDA Approval for Sovaldi for Treatment of Chronic Hepatitis C Virus Infection

Gilead Sciences, Inc. (NASDAQ:GILD) announced that the China Food and Drug Administration (CFDA) has approved …

Read more

Is It Premature to Celebrate Gilead Sciences, Inc.’s (GILD) Kite Pharma Momentum? Jefferies Looks Beyond the Recent Bull Rally

Analyst questions the bigger picture for GILD, including risks and visibility challenges wavering in 2018.

Read more

Cowen Shares Key Insights on Gilead Sciences, Inc. (GILD) Following Management Meetings

Gilead is very confident on the successful commercial launch of Axi-Cel.

Read more

Gilead Sciences, Inc. (GILD) Has Solid Catalysts for Continued Growth; William Blair Sets Fair Value at $87

Kite acquisition signals Gilead’s leadership and continued consolidation moving forward, says Katherine Xu

Read more